Effectiveness and Safety Evaluation of Aqueduct -100 Device

Not Applicable

Completed

• Conditions: Cervix Uteri Dilation
• Interventions: Device: Aqueduct -100

• Registration Number: NCT02941211
• Lead Sponsor: Aqueduct Medical Ltd

Brief Summary

Evaluation of efficacy and safety of using Aqueduct -100 - Cervical Dilator Device

Detailed Description

There are predominantly two major dilatation techniques that are employed in dilating the cervix. The first technique uses expansible dry solid material, such as laminaria (seaweed) is inserted into the cervix in its dried stiff form. In the cervix it comes into contact with body fluids that cause the laminaria to swell and enlarge the cervical cavity. The second more widespread procedure, involves the use of series of solid, rod like instruments of graduated diameter used in serial fashion by the physician (Hegar dilators). The physician first inserts a rod like dilator and replaces it with the dilator of next higher diameter. This procedure continues until adequate dilatation occurs.

The Problem is that each of the above-mentioned methods has its shortcomings: the use of the laminaria method (rarely done) requires preliminary patient visit, for insertion of the laminaria rod and is extremely slow and typically involves often as much as 10-12 hours for a significant amount of dilatation to occur.

The use of rod-like instruments (Hegar) requires general or regional anesthesia, when local anesthetics are used, the patient nevertheless frequently experiences a great amount of discomfort from the procedure. The mechanical dilatation of the cervix demands a large amount of longitudinal force that may damage or even puncture the cervix and the uterus.

Aqueduct 100 is a catheter for use in dilating various body cavities and especially the human cervix. The device will enable continuous, fast and safe dilatation of the cervix to a pre-determined diameter as a pre-procedure to intrauterine surgeries.

Study Timeline

• Study Start: 2015-01
• Primary Completion: 2015-11
• Study Completion: 2015-11
• Study First Submitted: 2016-08-30
• Status Verified: 2016-10
• Study First Submitted QC: 2016-10-20
• Last Update Submitted: 2016-10-20
• Study First Posted: 2016-10-21
• Last Update Posted: 2016-10-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

• Subjects, females, 18 years of age or older.
• Subjects undergoing any process that requires dilation (intrauterine procedures)
• Subjects willing to sign informed consent form.

Exclusion Criteria

• Subjects younger than 18 years of age
• Subject with sex transmitted diseases, or with infectious diseases (HIV, HCV).
• Subjects unwilling to sign the informed consent form.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Aqueduct 100 dilation	Aqueduct -100	Uterine cervix dilation through Aqueduct-100 device

Primary Outcome Measures

Name	Time	Method
Percentage of patients with dilation of cervix to the diameter needed to perform the intrauterine procedure using Aqueduct-100 device.	Through study completion, approximately 6 months	The primary outcome of this study is to determine the efficacy of the Aqueduct-100 device to dilate the uterine cervices to the desired diameter.

Secondary Outcome Measures

Name	Time	Method
Occurrence of Adverse Events	Through study completion, approximately 6 months	Safety evaluation of using Aqueduct-100

Trial Locations

Locations (1)

Hospital General Santa Maria del Puerto; 🇪🇸 Cádiz, Spain